EP0506815A1 - Nucleotides de mucine - Google Patents

Nucleotides de mucine

Info

Publication number
EP0506815A1
EP0506815A1 EP91901847A EP91901847A EP0506815A1 EP 0506815 A1 EP0506815 A1 EP 0506815A1 EP 91901847 A EP91901847 A EP 91901847A EP 91901847 A EP91901847 A EP 91901847A EP 0506815 A1 EP0506815 A1 EP 0506815A1
Authority
EP
European Patent Office
Prior art keywords
sequence
antibody
fragment
polypeptide
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91901847A
Other languages
German (de)
English (en)
Inventor
Joyce Taylor-Papadimitriou
Sandra Gendler
Joy Burchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Horizons Ltd
Original Assignee
Imperial Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Cancer Research Technology Ltd filed Critical Imperial Cancer Research Technology Ltd
Publication of EP0506815A1 publication Critical patent/EP0506815A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • MUCIN NUCLEOTIDES The present invention relates to nucleotide fragments, polypeptides and antibodies and their use in medical treatment and diagnosis.
  • International Patent Application no. WO-A-88/05054 there is disclosed a tandem repeat sequence contained in the human polymorphic epithelial mucin (HPEM) gene and nucleotide probes, polypeptides, antibodies and antibody-producing cells which are useful in the diagnosis and treatment of adenocarcinomas such as breast cancer.
  • HPEM human polymorphic epithelial mucin
  • the present inventors have now elucidated the nucleotide base sequence of the gene in the region 5' of the tandem repeat sequence (unless the context implies otherwise, directions such as “5'” or “3 ' " , "upstream” or “downstream” used herein refer to the non-template strand of the genomic DNA or fragments thereof).
  • the complete sequence of the 1763 nucleotide bases of the non-template strand upstream of and including the first Smal restriction site in the tandem repeat is set out in Fig. 1.
  • the sequence of 1575 nucleotide bases of the non- template strand upstream of and including the first Smal restriction site in the tandem repeat as set out in Fig. 3 has been extended and some parts have been corrected in the light of repeat experiments.
  • the template strand has a complementary sequence and it is this strand which is transcribed into RNA during expression of the gene product.
  • this sequence contains a number of features which may be important in the diagnosis and therapy of cancers and in expression of proteins from recombinant vectors. These features will be described below.
  • the amino acid sequence corresponding to the translated portions of this nucleotide sequence gives rise to peptides and thence to antibodies and antibody-producing cells which may also be useful in such diagnosis and treatment.
  • the present invention provides a nucleic acid fragment comprising a portion of at least 17 contiguous nucleotide bases which portion has a sequence the same as, or homologous to a portion of corresponding length of the sequence of the coding strand as set out in Fig. 1 or the same as, or homologous to a portion of corresponding length of the sequence complementary to the sequence of the coding strand set out in Fig. 1.
  • fragment is intended to include restriction endonuclease-generated nucleic acid molecules and synthetic oligonucleotides.
  • the nucleic acid fragments of the invention may be single-stranded or double-stranded and they may be RNA or DNA fragments.
  • Single stranded fragments may be "plus” or coding strands having the sequence of Fig. 1 or a part thereof or a sequence homologous thereto.
  • the single stranded fragments may be "minus" or non-coding strands having a sequence complementary to the sequence of Fig. 1 or a part thereof or a sequence homologous thereto.
  • Double stranded fragments contain a complementary pair of strands, (ie. one plus strand and one minus strand).
  • RNA fragments according to the invention will, of course, contain uridylic acid ("U”) residues in place of the deoxythymidylic acid residues ("T") of the coding (non-template) strand set out in Fig. 1 or, if complementary to the sequence of the coding strand, they will contain U residues in positions complementary to the adenylic acid (“A") residues in the coding strand set out in Fig. 1.
  • the nucleic acid fragments of the invention are double-stranded DNA fragments. Single-stranded nucleic acid fragments of the invention are at least 17 nucleotide bases in length. Double-stranded nucleic acid fragments of the invention are at least 17 nucleotide base pairs in length.
  • the fragments are at least 20 bases or base pairs in length, more preferably at least 25 bases or base pairs and yet more preferably at least 50 bases or base pairs in length.
  • a 17 nucleotide base sequence will be unique so that any nucleic acid fragment having a contiguous portion of 17 nucleotides of a sequence identical to a portion of corresponding length of the coding strand as set out in Fig. 1, or the same as the non-coding strand complementary to the sequence of Fig. 1, will be new.
  • Fragments according to the invention which are only 17 nucleotides or nucleotide bases in length have a sequence the same as, or complementary to, that set out in Fig.1.
  • Longer fragments of the invention may have a sequence which is homologous to a corresponding portion of the sequence for the coding strand as set out in Fig. 1 or to the complementary non-coding strand.
  • nucleic acid fragments according to the invention have at least 75% sequence homology with a corresponding portion of the sequence of Fig. 1 or the complementary non-coding strand, for instance 80 or 85%, more preferably 90 or even 95% homology. Differences may arise through deletions, insertions or substitutions.
  • nucleic acid fragments of the invention may include sequences completely unrelated to that in Fig. 1.
  • N is A, C, G or T W is A or T X is Y is C or T
  • Fig. 1 also includes two sites occurring in the promoter region and in the first intron having 70 to 80% homology with the mammary consensus, sequence (Rosen, J.M. in "The Mammary Gland, Development, Regulation and Function", Ed. Nevill, M.C. and Daniel, C.W. Plenum Press, pp 301-322). These sites are set out in Table 3 below:
  • Preferred fragments according to the present invention include the transcriptional and translational start signals, "TATAA” box and at least one of the regulatory elements (transcription factor binding sites) set out in Table 2 above. More preferably these fragments contain 2 or more, for instance 3, 4 or 5 of the regulatory elements in addition to the TATAA box or even all of the regulatory elements set out in Table 2. Those fragments containing more than one of the regulatory elements of Table 2 preferably also preserve the relative spacings of those sites from one another and from the TATAA box and transcriptional and translational start signals.
  • fragments of the invention contain at least one of the regions homologous to the mammary consensus sequences as set out in Table 3.
  • these fragments contain both of the regions having homology with the mammary consensus sequences as set out in Table 3.
  • Those fragments containing both regions having homology with the mammary consensus sequence preferably also preserve the relative spacing of those regions, as found in Fig. 1, from one another and from the TATAA box and transcriptional and translational start signals.
  • fragments according to the invention comprise the TATAA box, the transcriptional and translational start signals, at least one and preferably two or more of the regulatory elements as set out in Table 2 and at least one and preferably both of the regions having homology with the mammary consensus sequence as set out in Table 3. Yet more preferably these fragments also preserve the relative spacing of the features from Tables 1, 2 and 3.
  • Particularly preferred fragments according to the invention comprise the sequence upstream of the TATAA box as set out in Fig. 1 together with, and downstream thereof, transcriptional and translational start signals and a polypeptide coding sequence in correct reading frame register with the promoter sequences and the TATAA box, transcriptional and translational start signals.
  • the coding sequence may encode a part or parts of the polypeptide encoded by the mucin gene, for instance a part or parts thereof other than the tandem repeat sequence, or polypeptides unrelated to that encoded by the mucin gene.
  • Other particularly preferred fragments according to the present invention comprise promoter sequences, a TATAA box, transcriptional and translational start signals and, downstream thereof and in correct reading frame register therewith a coding sequence corresponding to a portion of the mucin gene, for instance corresponding to the first exon (corresponding to bases (1 to 130 of Fig.1.) or a part thereof and/or the second exon (corresponding to bases 633 onwards in Fig.1.) or a part thereof, for instance a part thereof other than the tandem repeat sequence as set out in WO-A-88/05054.
  • the fragments contain (i) the first 26 bases (bases 1 to 26 of Fig. 1) or (ii) the whole of the first exon (bases 1 to 130 of Fig.1.) and/or (iii) the splicing/ligating sites for the first intron set out in Table 1 and a non-coding sequence between these sites.
  • the non-coding sequence may be the same as or different to the sequence of the first intron as shown in Fig. 1. Preferably it is the same.
  • inventions comprise at least a portion of the first intron (bases 231 to 632 of Fig. 1). Further preferred fragments of the invention comprise at least a portion of the 5'-flanking sequence upstream of base -423 of Fig. 1.
  • Fragments according to the present invention containing functional coding sequences for a least a part of the first or second exons set out in Fig. 1 are useful in the production of polypeptides corresponding to a part or all of the mucin gene product.
  • Such polypeptides are, in turn useful as immunogenic agents for instance in active immunisation against Human Polymorphic Epithethial Mucin (HPEM) for the prophylactic or therapeutic treatment of cancers or raising antibodies for use in passive immunisation and diagnosis of cancers.
  • HPEM Human Polymorphic Epithethial Mucin
  • the fragment which codes for a polypeptide chain substantially identical to a portion of the mucin core protein, may be extended at either or both the 5' and 3' ends with further coding or non-coding nucleic acid sequence including regulatory and promoter sequences, marker sequences, and splicing or ligating sites. Coding sequences may code for other portions of the mucin core protein chain (for instance, other than the tandem repeat) or for other polypeptide chains.
  • the fragment according to the invention together with any necessary or desirable flanking sequences is inserted, in an appropriate open reading frame register, into a suitable vector such as a plasmid, or cosmid or a viral genome (for instance vaccinia virus genome) and is then expressed as a polypeptide product by conventional techniques.
  • a suitable vector such as a plasmid, or cosmid or a viral genome (for instance vaccinia virus genome)
  • the polypeptide product may be produced by culturing appropriate cells transformed with a vector, harvested and used as an immunogen to induce active immunity against the mucin core protein [Tartaglia et al., Tibtech, 6, 43: (1988)].
  • the fragments may be presented as inserts in a vector such as viral genomic nucleic acid and introduced into the patients by inoculation of the vector for instance as a modified virus.
  • the vector then directs expression of the polypeptide in vivo and this in turn serves as a therapeutic agent or as an immunogen to induce active immunity against the polypeptide.
  • This strategy may be adopted, for instance, to secure expression of polypeptides encoded by the HPEM gene for treatment or prophylaxis of adenocarcinomas such as breast cancer or to secure tissue specific expression of other peptides under control of the regulatory sequences of Table 1, for instance by administration of a modified vaccinia virus containing the fragment and coding sequences in its genomic DNA.
  • RNA fragments of the invention may similarly be used by administration via a retroviral vector. Selection of tissue specific virus vectors to carry the fragments of the invention and coding sequences will further restrict expression of the polypeptide to desired target tissues.
  • Fragments of the invention may also be used to control expression of oncogenic proteins in experimental transgenic animals.
  • a transgenic mouse having an oncogene such as ras, erbB-2 or int 2 expressed under control of the present tissue specific fragments may develop breast tumours and be useful in testing diagnostic agents such as tumour localisation and imaging agents and in testing therapeutic agents such as immunotoxins.
  • Nucleic acid fragments according to the invention are also useful as hybridisation probes for detecting the presence of DNA or RNA of corresponding sequence in a sample.
  • probes fragments are preferably labelled with a detectable label such as a radionuclide, enzyme label, fluorescent label or other conventional directly or indirectly detectable labels.
  • the probes may be bound to a solid support. Labelling of the probes may be achieved by conventional methods such as set out in Matthews et al., Anal. Biochem. 169: 1-25 (1988).
  • the present invention provides cloning vectors and expression vectors containing fragments according to the present invention.
  • the vectors may be, for instance, plasmids, cosmids or viral genomic DNA.
  • the present invention further provides host cells containing such cloning and expression vectors, for instance epithelial cells transformed with functional expression vectors containing expressible fragments according to the invention.
  • the invention further provides nucleic acid fragments which encode polypeptides as defined below. Such fragments may be fragments as hereinbefore defined. However, in view of the redundancy of the genetic code, nucleic acid sequences which differ slightly or substantially from the sequence of Fig. 2 may nevertheless encode the same polypeptide.
  • nucleic acid fragments of the invention may be produced de novo by conventional nucleic acid synthesis techniques or obtained from human epithelial cells by conventional methods, Huynh et al., "DNA Cloning: A Practical Approach” Glover, D.M. (Ed) IRL, Oxford, Vol 1, pp49-78 (1985).
  • the invention therefore also provides probes, vectors and transformed cells comprising nucleic acid fragments as hereinbefore defined for use in methods of treatment of the human or animal body by surgery or therapy and in diagnostic methods practiced on the human or animal body and for use in the preparation of medicaments for use in such methods.
  • the invention also provides methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practiced in vivo as well as ex vivo and in vitro which comprise administering such fragments, probes, vectors or transformed cells in effective non-toxic amount to a human or other mammal in need thereof.
  • Processes for producing fragments according to the invention and probes, vectors and transformed cells containing them and processes for expressing polypeptides encoded by, or under the regulatory control of, fragments of the invention also form aspects of the invention.
  • the invention further provides a polypeptide comprising a sequence of at least 5 amino acid residues encoded by the coding portion of the DNA sequence as indicated in Fig. 2.
  • Polypeptides according to the invention preferably have a sequence of at least 10 residues, for instance at least 15, more preferably 20 or more residues and most preferably all the residues shown in Fig. 2.
  • the polypeptide may additionally comprise N-terminal and/or C-terminal sequences not encoded by the DNA sequence indicated by Fig. 2.
  • Polypeptides of the invention containing more than 5 amino acid residues encoded by the DNA sequence in Fig. 2 may include minor variations by way of substitution, deletion or insertion of individual amino acid residues. Preferably such polypeptides differ at not more than 20% preferably not more than 10% and most preferably not more than 5% of residues in a contiguous portion corresponding to a portion of the sequence in Fig. 2.
  • the invention further provides polypeptides as defined above modified by addition of a linkage sugar such as N-acetyl galactosamine on serine and/or threonine residues and polypeptides modified by addition of oligosaccharide moieties to N-acetyl galactosamine or via other linkage sugars.
  • linkage sugar such as N-acetyl galactosamine on serine and/or threonine residues
  • polypeptides modified by addition of oligosaccharide moieties to N-acetyl galactosamine or via other linkage sugars.
  • optionally modified polypeptides linked to carrier proteins such as keyhole limpet haemocyanin, albumen or thyroglobulin are also within the invention.
  • Polypeptides according to the invention may be produced de novo by synthetic methods or by expression of the appropriate DNA fragments described above by recombinant DNA techniques and expressed without glycosylation in human or non-human cells. Alternatively they may be obtained by deglycosylating native human mucin glycoprotein (which itself may be produced by isolation from samples of human tissue or body fluids or by expression and full processing in a human cell line) [Burchell et al., Cancer Research, 47: 5467-5482, (1987), Gendler et al., P.N.A.S.. 84: 6060-6064, (1987)], and digesting the core protein.
  • native human mucin glycoprotein which itself may be produced by isolation from samples of human tissue or body fluids or by expression and full processing in a human cell line
  • the polypeptides of the invention are useful in active immunisation of humans, for raising antibodies in animals for use in passive immunisation, diagnostic tests, tumour localisation and, when used in conjunction with a cytotoxic agent, for tumour therapy.
  • the invention further provides antibodies against any of the polypeptides described above.
  • antibody is intended to include polyclonal and monoclonal antibodies and fragments of antibodies bearing antigen binding sites such as the F(ab') 2 fragments as well as such antibodies or fragments thereof which have been modified chemically or genetically in order to vary the amino acid residue sequence of one or more polypeptide chains, to change the species specific and/or isotype specific regions and/or to combine polypeptide chains from different sources.
  • the antibody may be appropriate to modify the antibody by coupling the Fab, or complementarity- determining region thereof, to the Fc, or whole framework, region of antibodies derived from the species to be treated (e.g. such that the Fab region of mouse monoclonal antibodies may be administered with a human Fc region to reduce immune response by a human patient) or in order to vary the isotype of the antibody (see EP-A-0 239 400).
  • Such antibodies may be obtained by conventional methods [Williams, Tibtech, 6:36, (1988)] and are useful in diagnostic and therapeutic applications, such as passive immunisation.
  • antibodies used herein is further intended to encompass antibody molecules or fragments thereof as defined above produced by recombinant DNA techniques as well as so-called “single domain antibodies” or “dAbs” such as are described by Ward, E.S. et al., Nature. 341:544-546 (1989) which are produced in recombinant microorganisms, such as Escherichia coli. harboring expressible DNA sequences derived from the DNA encoding the variable domain of an immunoglobulin heavy chain by random mutation introduced, for instance, during polymerise chain reaction amplification of the original DNA.
  • dAbs may be produced by screening a library of such randomly mutated DNA sequences and selecting those which enable expression of polypeptides capable of specifically binding the polypeptides of the invention or HPEM core protein.
  • Antibodies according to the present invention react with HPEM core protein, especially as expressed by colon, lung, ovary and particularly breast carcinomas, but have reduced or no reaction with corresponding fully processed HPEM.
  • the antibodies react with HPEM core protein but not with fully processed HPEM glycoprotein as produced by the normal lactating human mammary gland.
  • Antibodies according to the present invention preferably have no significant reaction with the mucin glycoproteins produced by pregnant or lactating mammary epithelial tissues but react with the mucin proteins expressed by mammary epithelial adenocarcinoma cells. These antibodies show a much reduced reaction with benign breast tumours and are therefore useful in diagnosis and localisation of breast cancer as well as in therapeutic methods. Further uses of the antibodies include diagnostic tests of assays for detecting and/or assessing the severity of breast, colon, ovary and lung cancers.
  • the antibodies may be used for other purposes including screening cell cultures for the polypeptide expression product of the human mammary epithelial mucin gene, or fragments thereof, particularly the nascent expression product.
  • the antibodies may conveniently be polyclonal or monoclonal antibodies.
  • the invention further provides antibodies linked to therapeutically or diagnostically effective ligands.
  • the ligands are lethal agents to be delivered to cancerous breast or other tissue in order to incapacitate or kill transformed cells.
  • Lethal agents include toxins, radioisotopes and "direct killing agents" such as components of complement as well as cytotoxic or other drugs.
  • the antibodies may be linked to ligands such as solid supports and detectable labels such as enzyme labels, chromophores, fluorophores and radioisotopes and other directly or indirectly detectable labels.
  • detectable labels such as enzyme labels, chromophores, fluorophores and radioisotopes and other directly or indirectly detectable labels.
  • monoclonal antibodies are used in diagnosis.
  • Antibodies according to the present invention may be produced by inoculation ,of suitable animals with a polypeptide as hereinbefore described.
  • Monoclonal antibodies are produced by known methods, for instance by the method of Kohler & Milstein [Nature, 256: 495-497 (1975)] by immortalising spleen cells from an animal inoculated with the mucin core protein or a fragment thereof, usually by fusion with an immortal cell line
  • a myeloma cell line (preferably a myeloma cell line), of the same or a different species as the inoculated animal, followed by the appropriate cloning and screening steps.
  • Antibody-producing cells obtained from animals inoculated with polypeptides of the invention and immortalised such cells form further aspects of the invention.
  • the invention further provides polypeptides, antibodies and antibody producing cells, such as hybridomas, as hereinbefore defined for use in methods of surgery, therapy or diagnosis practiced on the human or animal body or for use in the production of medicaments for use in such methods.
  • the invention also provides a method of treatment or diagnosis which comprises administering an effective non-toxic amount of a polypeptide or antibody as hereinbefore described to a human or animal in need thereof.
  • Processes for producing polypeptides according to the invention whether by expression of nucleic acid fragments of the invention of otherwise, and for producing antibodies or fragments thereof and for producing antibody-producing cells such as immortalised cells, form further aspects of the invention.
  • the invention further provides a diagnostic test or assay method comprising contacting a sample suspected to contain abnormal human mucin glycoproteins with an antibody as defined above.
  • diagnostic test or assay methods include tumour localisation involving administration to the patient of the antibody bearing detectable label or administration of an antibody and, separately, simultaneously or sequentially in either order, administering a labelling entity capable of selectively binding the antibody or fragment thereof.
  • Diagnostic test kits are provided for use in diagnostic tests or assays and comprise antibody and, optionally, suitable labels and other reagents and, especially for use in competitive assays, standard sera.
  • Fig. 1 shows the deoxynucleotide base sequence of the 1763 bases upstream of and including the first Smal restriction site in the tandem repeat sequence of WO-A-88/05054 using the conventional symbols A, C, G and T for the bases of the non-template strand.
  • the base sequence is arranged in blocks of ten. Untranscribed sequence is in lower case, transcribed sequence is in upper case.
  • the SP1 regulatory elements (Table 2), TATAA box, transcriptional and translational start sites (Table 1) are underlined.
  • Fig. 2. shows the sequence of the non-template strand commencing from the transcriptional start site, (residue 1 in Fig.
  • Fig.2 also shows the predicted sequence of the polypeptide using the conventional 1 letter symbols for the amino acid residues. Amino acid residues are numbered down the left-hand side and nucleotide bases down the right hand side. The signal sequence is underlined. The sequences end at the first Smal site in the tandem repeat.
  • Fig. 3. shows the deoxy nucleotide base sequence of the 1575 bases upstream of and including the first Smal restriction site in the tandem repeat sequence of WO-A-88/05054 using the conventional symbols A, C, G and T for the bases of the non-template strand.
  • the base sequence is arranged in blocks of ten in non-coding regions.
  • the exon sequences are shown in blocks of three and translated codons are underlined.
  • the start positions of exons 1 and 2, intron 1 and the signal sequence for exon splicing are numbered and labelled, other features mentioned in Tables 1 and 2 are boxed.
  • the present invention does not extend to fragments, polypeptides and antibodies or related materials such as vectors and cells, which are specifically disclosed in WO-A- 88/05054 or WO-A-90/05142, nor to the CDNA fragment whose sequence is indicated in Abe, M. et al., in Biochemical and Biophysical Research Communications, 165(2): 644-649 (1989).
  • RNA 5 ⁇ g
  • guanidinium isothiocyanate method guanidinium isothiocyanate method
  • BT20 breast cancer cell line
  • AMV-reverse transcriptase Life Sciences
  • RNA was subjected to reverse transcription, and the products were precipitated with spermine.
  • a poly(dG) tail was introduced with terminal deoxy-transferase (500 U/ml, Pharmacia).
  • Amplification was performed with Thermus aquaticus polymerise (Perkin Elmer Cetus) in 100 ⁇ l of the standard buffer supplied.
  • the primers included the tandem repeat primer and for the poly(dG) end, a mixture of the A polyC primer (5'GCATGCGCGCGGCCGCGGAGGCCCCCCCCCCCCCC3') and the AN primer (5'GCATGCGCGCGGCCGCGGAGGCC3') at a ratio of 1:9. Following an initial denaturation at 94°C for 5 min, the reaction was annealed at 55°C for 2 min, extended at 72°C for 2.5 min and denatured at 94°C for 1.5 min.
  • the primer extension technique was use to map precisely the position of the capsite.
  • a 21 bp oligonucleotide primer (5'AGACTGGGTGCCCGGTGTCAT3') corresponding to nucleotides 73 to 93 ending at the A of ATG (Fig. 1) was end-labelled with [ ⁇ - 32 P]ATP (> 5000 Ci/mmol, Amersham International pic) using T4 poly-nucleotide kinase (Pharmacia) and precipitated three times with equal volumes of 4 M ammonium acetate to remove free [ ⁇ - 32 P]ATP from the kinased oligonucleotide.
  • Labelled primer (1 x 10 5 dpm at 1 x 10 7 dpm/pmole) was annealed to 40 ⁇ g of total BT 20 RNA in 120 mM sodium chloride at 95°C for 5 min, held at 65°C for 1 h and cooled to room temperature.
  • the annealed primer was extended using 18 units of reverse transcriptase in 50mM Tris pH 8.3 at 45°C, 6 mM magnesium acetate, 10 mM dithiothreitol, 1.8 mM dNTPs in a total volume of 50 ⁇ l at 45°C for lh.
  • the reaction was stopped by the addition of 50 mM EDTA and the RNA digested by treatment with RNase-A at 400 ⁇ g/ml for 15 min at 37°C.
  • the samples were than phenol:chloroform extracted prior to ethanol precipitation and electrophoresed on a standard 6% sequencing gel yielding two bands which mapped to two C's, 72 and 71 bases upstream of the ATG.
  • the sequencing ladder was single-stranded control DNA (M13mp18) from the Sequenase kit (US Biochemical Corp.).
  • the most prominent product was 72 bp, equal to the number of base pairs from the 5' end of the oligonucleotide primer to the 5' end of the PCR-derived clone, thus confirming that the cDNA represents the entire length of its corresponding cellular mRNA 5' to the tandem repeat.
  • the presence of a second band may be due to interference with reverse transcriptase by methylation of the C at base 71, since it forms a CpG dinucleotide.
  • no primer extension product was seem using RNA from Daudi cells which do not express the PEM mucin.
  • Fig 1. shows the DNA sequence from the 5' A-PCR-derived clone, including the consensus sequence of the tandem repeat. Sequences were determined in both directions. The region of conserved tandem repeats was not sequenced in full, although a cDNA tandem repeat clone obtained previously had been circularised, sonicated and about 40 clones sequences [(Gendler et al., J. Biol. Chem., 263:12820-12823 (1988)].
  • the core protein amino acid composition is dominated by the amino acid composition of the tandem repeat. Serine, threonine, proline, alanine and glycine account for about 60% of the amino acids.
  • the deduced sequence of the PEM core protein consists of distinct regions including (1) the N-terminal region containing a hydrophobic signal sequence and degenerate tandem repeats and (2) the tandem repeat region itself.
  • a putative signal peptide of 13 amino acids follows the first 7 amino acids.
  • the actual site of cleavage has not been determined as attempts to obtain N-terminal sequence of the core protein were hindered by a blocked amino terminus.
  • Following the signal sequence and preceding the first Smal site (which is used to define the beginning of the tandem repeat region) are 107 amino acids. Greater than 50% of these amino acids comprise degenerate tandem repeats.
  • tandem repeats per molecule Since the number of tandem repeats per molecule is large (greater than 21 for the smallest allele we have observed), this domain forms the major part of the core protein, and results in a highly repetitive structure which is extremely immunogenic [Gendler, S. et al., loc. cit].
  • the sequence of the 20 amino acid tandem repeat unit corresponds to what might be expected for a protein which is extensively O-glycosylated. Five serines and threonines, four of which are in doublets, are found in the repeat and these potential glycosylation sites are separated by regions rich in prolines (See Fig. 2).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Fragment d'acide nucléique comprenant une partie d'au moins 17 bases de nuclétodies contiguës, ladite partie présente une séquence identique ou homologue à une partie de longueur correspondante de la séquence du brin codant représentée par la figure 1, ou identique ou homologue à une partie de longueur correspondante de la séquence complémentaire à la séquence du brin codant représentée dans la figure 1.
EP91901847A 1989-12-22 1990-12-24 Nucleotides de mucine Withdrawn EP0506815A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898929097A GB8929097D0 (en) 1989-12-22 1989-12-22 Mucin nucleotides
GB8929097 1989-12-22

Publications (1)

Publication Number Publication Date
EP0506815A1 true EP0506815A1 (fr) 1992-10-07

Family

ID=10668442

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91901847A Withdrawn EP0506815A1 (fr) 1989-12-22 1990-12-24 Nucleotides de mucine

Country Status (4)

Country Link
EP (1) EP0506815A1 (fr)
JP (1) JPH05502789A (fr)
GB (1) GB8929097D0 (fr)
WO (1) WO1991009867A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
CA2153068C (fr) * 1992-12-31 2007-05-01 Donald Kufe Sequence stimulatrice pour la modulation de l'expression dans les cellules epitheliales
IL110464A0 (en) * 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
DE19547324C2 (de) * 1995-12-19 1997-10-16 Behringwerke Ag Humanes Muzin (MUC8)
GB9708190D0 (en) * 1997-04-23 1997-06-11 Univ Leicester Cancer marker
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
EP1257565A4 (fr) * 2000-02-01 2005-04-06 Austin Research Inst Antigenes derives de mucine-1 et leur utilisation en immunotherapie
AU780395B2 (en) * 2000-02-01 2005-03-17 Austin Research Institute, The Mucin-1 derived antigens and their use in immunotherapy
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
JP4276432B2 (ja) 2000-12-22 2009-06-10 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｍｕｃ１による細胞増殖調節方法
WO2005042573A1 (fr) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation de l'interaction de muc1 avec des ligands de muc1
WO2008097840A2 (fr) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Méthodes et compositions associées à la régulation de muc1 par hsf1 et stat3
WO2008097844A2 (fr) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Méthodes et compositions associées à la régulation de l'apoptose par des protéines muc1 et des protéines pro-apoptotiques contenant seulement le domaine bh3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339204C (fr) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Polypeptides, anticorps et sondes a noyau de mucine
JPH04501719A (ja) * 1988-11-10 1992-03-26 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド ポリペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9109867A1 *

Also Published As

Publication number Publication date
GB8929097D0 (en) 1990-02-28
WO1991009867A1 (fr) 1991-07-11
JPH05502789A (ja) 1993-05-20

Similar Documents

Publication Publication Date Title
Gendler et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.
Nedellec et al. Bgp2, a new member of the carcinoembryonic antigen-related gene family, encodes an alternative receptor for mouse hepatitis viruses
Neumaier et al. Characterization of a cDNA clone for the nonspecific cross-reacting antigen (NCA) and a comparison of NCA and carcinoembryonic antigen.
KR960002874B1 (ko) 재조합된 사람의 내피 세포 성장 인자의 제조방법
DK174927B1 (da) DNA, der koder for human faktor VIII:C, vektor omfattende denne DNA, transformeret vært omfattende denne DNA, og fremgangsmåde til fremstilling af human faktor VIII:C
EP2045322B1 (fr) Musculation double chez les mammifères
Hirayoshi et al. HSP47: a tissue-specific, transformation-sensitive, collagen-binding heat shock protein of chicken embryo fibroblasts
DK171601B1 (da) Rekombinant DNA, som koder for beta-underenheden eller den umodne beta-underenhed af humant FSH, vektorer omfattende den rekombinante DNA, værtsceller transformeret med vektorerne, fremgangsmåde til fremstilling af beta-underenheden eller dens umodne form samt den umodne beta-underenhed af humant FSH
JPH05508308A (ja) 血小板細胞付着分子とその変種
EP0506815A1 (fr) Nucleotides de mucine
JP2000350582A (ja) 新規の７−トランスメンブランレセプター
WO1996013514A1 (fr) Gene et proteine tcl-1, methodes et compositions associees
WO1992006194A1 (fr) Sequences nucleotides codant pour une proteine humaine possedant des proprietes de regulation de l'angiogenese
JPH10507343A (ja) 網膜芽細胞腫タンパク質相互作用性ジンクフィンガータンパク質
JPH05509234A (ja) ヒトＴリンパ球レセプターのα鎖の可変領域をコードするヌクレオチド配列対応するペプチドセグメント並びに診断及び治療への利用
Huopaniemi et al. Characterization of two unusual RS1 gene deletions segregating in Danish retinoschisis families
EP0769053A2 (fr) Produits et procedes relatifs au diagnostic et au traitement prophylactique et therapeutique du synoviosarcome
US6544759B1 (en) Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
US5731192A (en) Collagen COL4A6: gene, protein and method of detecting collagen deficiency
Peacock et al. Analysis of a human gene homologous to rat ventral prostate. 1 protein
CA2367468C (fr) Gene de la polyarthrite rhumatoide et procede permettant de diagnostiquer la polyarthrite rhumatoide
US5874264A (en) Gibbon ape leukemia virus receptor
US7067635B2 (en) Nucleotide and deduced amino acid sequences of tumor gene Int6
JPH06503475A (ja) 生来のタイプ２ｇａｐ、種々のｇａｐの精製方法及び癌診断へのｇａｐの使用
JPH07289297A (ja) 癌抑制遺伝子

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19941021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19941214